- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | FDA approves Deciphera's Romvimza for rare tumour type | ||
| Mi | UK study highlights importance of GP data in understanding atrial fibrillation | ||
| Di | NHS England launches first-ever breast cancer screening campaign | ||
| Mo | Cambridge scientists develop 'super test' for prostate cancer | ||
| Mo | Bath researchers awarded Wellcome grant for psychotic disorder study | ||
| 13.02. | Andembry treatment approved across Europe | ||
| 13.02. | Illuccix therapy gets approval in the UK | ||
| 12.02. | Amlenetug receives FDA Fast Track Designation | ||
| 12.02. | Bimekizumab shows long-term efficacy in hidradenitis suppurativa | ||
| 11.02. | Libtayo available in Scotland for cervical cancer patients | ||
| 11.02. | Lynparza approved in Scotland for BRCA-mutated breast cancer patients | ||
| 10.02. | Capgemini unveils AI breakthrough to boost bioeconomy | ||
| 10.02. | Hemgenix shows efficacy among haemophilia B patients | ||
| 06.02. | Qureight and Avalyn launch strategic partnership in pulmonary fibrosis | ||
| 06.02. | FDA grants Orphan Drug Designation to Ariceum cancer therapy | ||
| 05.02. | Novartis secures MHRA authorisation for ribociclib | ||
| 04.02. | Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies | ||
| 04.02. | Algiax announces results from phase 2a trial for neuropathic pain treatment | ||
| 03.02. | Aplagon secures EUR 7 million for APAC phase 2a trials | ||
| 03.02. | CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients | ||
| 28.01. | Cartesian Therapeutics announces FDA agreement for new trial | ||
| 28.01. | FDA approves new Alzheimer's treatment regimen | ||
| 27.01. | Vedanta Biosciences reveals Phase 2 VE303 results | ||
| 27.01. | Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX | ||
| 23.01. | Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
